TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01292031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 2 g/iv/ 8 h. 30 minutes infusion
Study: NCT03478956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
Study: NCT02610426

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03048331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause.
Study: NCT01722669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoquercetin or quercetin
Description: Single dose PK/PD study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoquercetin or quercetin
Description: Single dose PK/PD study
Study: NCT02128022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (7-36) amide
Description: Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 (7-36) amide
Description: Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Oral Glibenclamide 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Oral Glibenclamide 5mg
Study: NCT04581811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged Proned Positioning
Description: Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Proning Arm
Description: Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
Study: NCT03762590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doxy.me genetic education +/- Color Genomics genetic education
Description: Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Color Genomics genetic education
Description: Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
Study: NCT02927964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given IT
Study: NCT04411992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Device
Description: The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Device
Description: The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
Study: NCT02828358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, SC, IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO, NG, IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given PO, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO, IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO, NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO, NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO, NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03371212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual mobility cohort
Description: Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell.
Study: NCT01577108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: oral taking 2 capsules before sleeping per day for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral taking 2 capsules before sleeping per day for 14 days
Study: NCT04301037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension band wires
Description: medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulated screws
Description: In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
Study: NCT03726411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Description: scaling and root planing
Study: NCT05146895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod treatment
Description: As an control arm, for patients with flat warts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local Hyperthermia at 44℃
Description: As an experimental arm, for patients with flat warts
Study: NCT05510375

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study: NCT01267045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
Study: NCT02624752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Comparison of enhanced oral nutrition supplementation versus standard of care
Study: NCT02339584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 10 mg/mL eye drops, suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 2 mg/mL eye drops, solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT02095093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellijoint HIP
Description: Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Outrigger
Description: The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
Study: NCT01402011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25% dextrose in shoulder entheses
Description: injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: .1% lidocaine in shoulder entheses
Description: injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: .1% lidocaine subcu. above shouldr enth.
Description: injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
Study: NCT03371212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cohort
Description: Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components \> 52mm), polyethylene bearing, and G7 acetabular shell
Study: NCT04323046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03607487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 tablet administered orally once daily at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally once daily.
Study: NCT02836093

Intervention type: BEHAVIORAL
Intervention: FACIT-Fatigue 52-point questionnaire
Study: NCT01684956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection
Study: NCT00818480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: continuous infusion
Study: NCT01980940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% DMSO Gel
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 75 mg 4% PG Gel
Description: Etoricoxib 75 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% DMSO Gel
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% PG Gel
Description: Etoricoxib 150 mg 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% PG Gel
Description: Etoricoxib 150 mg 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% PG Gel
Description: Etoricoxib 150 mg 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 150 mg 4% PG Gel
Description: Etoricoxib 150 mg 4% PG gel applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 163 mg 4% DMSO gel
Description: Etoricoxib 163 mg 4% DMSO gel applied topically
Study: NCT04323046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies, given in person or online

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies, given in person or online
Study: NCT05594186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.
Description: Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
Study: NCT02035657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A in Stable Emulsion
Study: NCT01395745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blisibimod
Description: blisibimod administered via subcutaneous injection every week for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered weekly via subcutaneous injection for 52 weeks
Study: NCT02085720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
Study: NCT02720458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized gradual hypnotic taper
Description: The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized gradual hypnotic taper
Description: The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term simple self-help program
Description: The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program.